ERBB2 and breast cancer: BC expresses different molecular markers, including estrogen receptors (ER), progesterone receptors (PR) and HER2, leading to molecular subtypes with a different risk of developing CNS recurrences and survival; thus, the molecular profile should be obtained to tailor treatments [152].